Halter Ferguson Financial Inc. Buys 83,363 Shares of Candel Therapeutics, Inc. $CADL

Key Points

• Halter Ferguson Financial Inc. increased its stake in Candel Therapeutics by 12.0%, owning approximately 776,516 shares, making it the firm's 9th largest holding.
• Candel Therapeutics recently faced analyst downgrades from Bank of America as they cut their stock rating to neutral with a price target of $7.00, while HC Wainwright raised their rating to buy with a $23.00 target.
• The company's stock is currently priced at $4.81 with a market capitalization of $264.07 million, following a recent 2.6% decline in stock value.

Halter Ferguson Financial Inc. lifted its stake in Candel Therapeutics, Inc. (NASDAQ:CADL - Free Report) by 12.0% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 776,516 shares of the company's stock after purchasing an additional 83,363 shares during the quarter. Candel Therapeutics comprises about 1.4% of Halter Ferguson Financial Inc.'s holdings, making the stock its 9th largest holding. Halter Ferguson Financial Inc. owned 1.55% of Candel Therapeutics worth $3,929,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Northern Trust Corp grew its holdings in Candel Therapeutics by 3.9% during the 4th quarter. Northern Trust Corp now owns 165,021 shares of the company's stock valued at $1,432,000 after buying an additional 6,250 shares during the last quarter. BNP Paribas Financial Markets acquired a new position in Candel Therapeutics in the fourth quarter worth approximately $30,000. Bank of America Corp DE grew its position in Candel Therapeutics by 205.6% during the 4th quarter. Bank of America Corp DE now owns 66,811 shares of the company's stock worth $580,000 after purchasing an additional 44,952 shares in the last quarter. Deutsche Bank AG lifted its stake in shares of Candel Therapeutics by 5,814.1% in the 4th quarter. Deutsche Bank AG now owns 31,522 shares of the company's stock valued at $274,000 after purchasing an additional 30,989 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Candel Therapeutics by 12.4% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,165 shares of the company's stock worth $106,000 after acquiring an additional 1,340 shares during the period. Hedge funds and other institutional investors own 13.93% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the stock. Brookline Capital Management raised shares of Candel Therapeutics to a "strong-buy" rating in a research note on Wednesday, July 9th. HC Wainwright raised shares of Candel Therapeutics to a "buy" rating and set a $23.00 target price on the stock in a report on Monday, June 30th. Bank of America lowered shares of Candel Therapeutics from a "buy" rating to a "neutral" rating and reduced their target price for the stock from $13.00 to $7.00 in a report on Wednesday, September 3rd. Finally, Wall Street Zen raised shares of Candel Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus target price of $20.00.

Candel Therapeutics Price Performance

Shares of CADL stock traded down $0.13 on Friday, reaching $4.81. The company's stock had a trading volume of 928,141 shares, compared to its average volume of 705,384. The company has a current ratio of 7.04, a quick ratio of 7.04 and a debt-to-equity ratio of 0.01. The stock's fifty day simple moving average is $5.90 and its 200-day simple moving average is $5.75. The company has a market capitalization of $264.07 million, a price-to-earnings ratio of -6.97 and a beta of -0.90. Candel Therapeutics, Inc. has a 1 year low of $3.79 and a 1 year high of $14.60.

Candel Therapeutics (NASDAQ:CADL - Get Free Report) last issued its quarterly earnings results on Thursday, August 14th. The company reported ($0.09) earnings per share for the quarter, topping analysts' consensus estimates of ($0.17) by $0.08. Analysts forecast that Candel Therapeutics, Inc. will post -1.47 earnings per share for the current fiscal year.

Candel Therapeutics Company Profile

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.